Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study.

CONTEXT Somatic mutations in PRKACA gene, encoding the catalytic subunit of protein kinase A (PKA), have been recently found in a high proportion of sporadic adenomas associated with Cushing's syndrome. The aim was to analyze the PRKACA mutation in a large cohort of patients with adrenocortical masses. METHODS Samples from nine European centers were included (Germany, n = 4; Italy, n = 4; France, n = 1). Samples were drawn from 149 patients with nonsecreting adenomas (n = 32 + 2 peritumoral), subclinical hypercortisolism (n = 36), Cushing's syndrome (n = 64 + 2 peritumoral), androgen-producing tumors (n = 4), adrenocortical carcinomas (n = 5 + 2 peritumoral), and primary bilateral macronodular adrenal hyperplasias (n = 8). Blood samples were available from patients with nonsecreting adenomas (n = 15), subclinical hypercortisolism (n = 10), and Cushing's syndrome (n = 35). Clinical and hormonal data were collected. DNA amplification by PCR of exons 6 and 7 of the PRKACA gene and direct sequencing were performed. RESULTS PRKACA heterozygous mutations were found in 22/64 samples of Cushing's syndrome patients (34%). No mutations were found in peritumoral tissue and blood samples or in other tumors examined. The c.617A>C (p.Leu206Arg) occurred in 18/22 patients. Furthermore, two novel mutations were identified: c.600_601insGTG/p.Cys200_Gly201insVal in three patients and c.639C>G+c.638_640insATTATCCTGAGG/p.Ser213Arg+p.Leu212_Lys214insIle-Ile-Leu-Arg) in one. All the mutations involved a region implicated in interaction between PKA regulatory and catalytic subunits. Patients with somatic PRKACA mutations showed higher levels of cortisol after dexamethasone test and a smaller adenoma size, compared with nonmutated subjects. CONCLUSIONS These data confirm and extend previous observations that somatic PRKACA mutations are specific for adrenocortical adenomas causing Cushing's syndrome.

[1]  U. Pagotto,et al.  Validation of an LC–MS/MS salivary assay for glucocorticoid status assessment: Evaluation of the diurnal fluctuation of cortisol and cortisone and of their association within and between serum and saliva , 2016, The Journal of Steroid Biochemistry and Molecular Biology.

[2]  Martin Reincke,et al.  Subclinical hypercortisolism: a state, a syndrome, or a disease? , 2015, European journal of endocrinology.

[3]  F. Beuschlein,et al.  cAMP signaling in cortisol-producing adrenal adenoma. , 2015, European journal of endocrinology.

[4]  L. Nieman,et al.  Cushing's syndrome , 2015, The Lancet.

[5]  R. Golfieri,et al.  Steroid Profiling by LC-MS/MS in Nonsecreting and Subclinical Cortisol-Secreting Adrenocortical Adenomas. , 2015, The Journal of clinical endocrinology and metabolism.

[6]  G. Di Dalmazi,et al.  Adrenal adenomas, subclinical hypercortisolism, and cardiovascular outcomes , 2015, Current opinion in endocrinology, diabetes, and obesity.

[7]  F. Beuschlein,et al.  Time to recovery of adrenal function after curative surgery for Cushing's syndrome depends on etiology. , 2015, The Journal of clinical endocrinology and metabolism.

[8]  T. Wieland,et al.  Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas. , 2015, The Journal of clinical endocrinology and metabolism.

[9]  M. Debono,et al.  Faculty Opinions recommendation of Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing's syndrome: a European multicentric study. , 2014 .

[10]  F. Beuschlein,et al.  Adrenal function after adrenalectomy for subclinical hypercortisolism and Cushing's syndrome: a systematic review of the literature. , 2014, The Journal of clinical endocrinology and metabolism.

[11]  Minghui He,et al.  Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome , 2014, Science.

[12]  O. Nureki,et al.  Recurrent somatic mutations underlie corticotropin-independent Cushing’s syndrome , 2014, Science.

[13]  R. Golfieri,et al.  Cardiovascular events and mortality in patients with adrenal incidentalomas that are either non-secreting or associated with intermediate phenotype or subclinical Cushing's syndrome: a 15-year retrospective study. , 2014, The lancet. Diabetes & endocrinology.

[14]  D. Dietrich,et al.  Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors , 2014, Nature Genetics.

[15]  T. Wieland,et al.  Constitutive activation of PKA catalytic subunit in adrenal Cushing's syndrome. , 2014, The New England journal of medicine.

[16]  G. Di Dalmazi,et al.  Cross-talk between adipose tissue and the HPA axis in obesity and overt hypercortisolemic states , 2014, Hormone molecular biology and clinical investigation.

[17]  G. Di Dalmazi,et al.  Androgen profiling by liquid chromatography-tandem mass spectrometry (LC-MS/MS) in healthy normal-weight ovulatory and anovulatory late adolescent and young women. , 2013, The Journal of clinical endocrinology and metabolism.

[18]  G. Di Dalmazi,et al.  The unrelenting fall of the pharmacological treatment of obesity , 2013, Endocrine.

[19]  E. Ghigo,et al.  Long-term follow-up in adrenal incidentalomas: an Italian multicenter study. , 2014, The Journal of clinical endocrinology and metabolism.

[20]  G. Fava,et al.  Prevalence of hyperandrogenic states in late adolescent and young women: epidemiological survey on italian high-school students. , 2013, The Journal of clinical endocrinology and metabolism.

[21]  G. Di Dalmazi,et al.  Glucocorticoids and Type 2 Diabetes: From Physiology to Pathology , 2012, Journal of nutrition and metabolism.

[22]  F. Faucz,et al.  Identification of novel genetic variants in phosphodiesterase 8B ( PDE8B ), a cAMP‐specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours , 2012, Clinical endocrinology.

[23]  D. Santini,et al.  Combined Aldosterone and Cortisol Secretion by Adrenal Incidentaloma , 2012, International journal of surgical pathology.

[24]  G. Arnaldi,et al.  Advances in the epidemiology, pathogenesis, and management of Cushing’s syndrome complications , 2012, Journal of Endocrinological Investigation.

[25]  C. Mosconi,et al.  Progressively increased patterns of subclinical cortisol hypersecretion in adrenal incidentalomas differently predict major metabolic and cardiovascular outcomes: a large cross-sectional study. , 2012, European journal of endocrinology.

[26]  C. Stratakis,et al.  The cAMP pathway and the control of adrenocortical development and growth , 2012, Molecular and Cellular Endocrinology.

[27]  Susan S. Taylor,et al.  Structure and Allostery of the PKA RIIβ Tetrameric Holoenzyme , 2012, Science.

[28]  W. Young,et al.  Primary Bimorphic Adrenocortical Disease: Cause of Hypercortisolism in McCune-Albright Syndrome , 2011, The American journal of surgical pathology.

[29]  G. Di Dalmazi,et al.  Cortisol, energy intake, and food frequency in overweight/obese women. , 2011, Nutrition.

[30]  J. Beavo,et al.  The High-Affinity cAMP-Specific Phosphodiesterase 8B Controls Steroidogenesis in the Mouse Adrenal Gland , 2011, Molecular Pharmacology.

[31]  C. Nanni,et al.  I-123 MIBG scintigraphy and 68Ga-DOTANOC PET/CT negative but F-18 DOPA PET/CT positive pheochromocytoma: a case report. , 2011, Clinical nuclear medicine.

[32]  C. Cheadle,et al.  Integrated genomic analysis of nodular tissue in macronodular adrenocortical hyperplasia: progression of tumorigenesis in a disorder associated with multiple benign lesions. , 2011, The Journal of clinical endocrinology and metabolism.

[33]  E. Mignot,et al.  Body mass index-independent metabolic alterations in narcolepsy with cataplexy. , 2009, Sleep.

[34]  V. Montori,et al.  The diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline. , 2008, The Journal of clinical endocrinology and metabolism.

[35]  P. Gregersen,et al.  Adrenal hyperplasia and adenomas are associated with inhibition of phosphodiesterase 11A in carriers of PDE11A sequence variants that are frequent in the population. , 2006, Cancer research.

[36]  L. Nieman,et al.  Cushing's syndrome , 2005 .

[37]  J. Bertherat,et al.  Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. , 2003, Cancer research.

[38]  D. Marsh,et al.  Comparative genomic hybridization analysis of adrenocortical tumors. , 2002, The Journal of clinical endocrinology and metabolism.

[39]  J. Bertherat,et al.  Role of the PKA‐Regulated Transcription Factor CREB in Development and Tumorigenesis of Endocrine Tissues , 2002, Annals of the New York Academy of Sciences.

[40]  G. Arnaldi,et al.  Variable expression of the transcription factors cAMP response element-binding protein and inducible cAMP early repressor in the normal adrenal cortex and in adrenocortical adenomas and carcinomas. , 2001, The Journal of clinical endocrinology and metabolism.

[41]  C. Stratakis,et al.  Mutations of the gene encoding the protein kinase A type I-α regulatory subunit in patients with the Carney complex , 2000, Nature Genetics.

[42]  C. Larsson,et al.  Genetic aberrations in adrenocortical tumors detected using comparative genomic hybridization correlate with tumor size and malignancy. , 1996, Cancer research.

[43]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[44]  C. Plotz,et al.  The natural history of Cushing's syndrome. , 1952, The American journal of medicine.

[45]  G. Di Dalmazi.  The landscape of bilateral adrenal incidentalomas associated with subclinical hypercortisolism. , 2016, Endocrine.

[46]  C. Stratakis.  Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin- independent Cushing syndrome). , 2008, Endocrine development.

[47]  C Hagen,et al.  Incidence and late prognosis of cushing's syndrome: a population-based study. , 2001, The Journal of clinical endocrinology and metabolism.

[48]  J. Scott.  Cyclic nucleotide-dependent protein kinases. , 1991, Pharmacology & therapeutics.